Company: MYSEW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001013762-25-004290
Chunk: 277

Company: Myseum, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 277
---
268058), which was declared effective by the Securities and Exchange Commission on December 6, 2022,
a base prospectus dated December 6, 2022, and a prospectus supplement dated January 8, 2025. The closing of the offering took place on
January 9, 2025. In addition, pursuant to the terms of the offering, the Company issued to The Benchmark Company, LLC, the exclusive placement
agent for the offering, warrants to purchase up to 60,000 shares of the Company’s common stock, at an exercise price equal
to 100.0% of the offering price per share of Common Stock, or $4.25 per share. The Placement Agent Warrant is exercisable during the four-and-a-half
year period commencing six months after the date of the closing of this Offering.

Basis of Presentation

The financial statements contained herein have
been prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”)
and the requirements of the Securities and Exchange Commission.

Critical Estimates

This management’s discussion and analysis
of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S.
GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported
amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements,
and the reported amounts of revenue and expenses during the reported period. In accordance with U.S. GAAP, we base our estimates on historical
experience and on various other assumptions we believe to be reasonable under the circumstances. Actual results may differ from these
estimates if conditions differ from our assumptions. While our significant accounting policies and significant estimates are more fully
described in Note 2 in the “Notes to Financial Statements”, we believe the following estimates are critical to the process
of making significant judgments and estimates in preparation of our consolidated financial statements.

Capitalized internal-use software costs

We capitalize costs to develop or purchase internal-use software in
accordance with ASC section 350-40, Intangibles — Goodwill and Other — Internal-Use Software.
Costs incurred to develop internal-use software are expensed as incurred during the preliminary project stage. Internal-use software development
costs are capitalized upon purchase and during the application development stage, which is after: (i) the preliminary project stage is
completed;